Clinical Trial: Bioavailability of Ubiquinol in Huntington Disease

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Bioavailability of Ubiquinol in Huntington Disease

Brief Summary:

The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.

Detailed Summary:
Sponsor: University of Rochester

Current Primary Outcome: serum coenzyme Q10 levels [ Time Frame: 8 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Rochester

Dates:
Date Received: September 17, 2009
Date Started: September 2009
Date Completion:
Last Updated: May 25, 2016
Last Verified: May 2016